# Leveraging MEDITECH electronic health record (EHR) functionality to support the implementation of a biosimilar

## Guide Objectives

An EHR system can have a substantial impact on an organization's biosimilar implementation plan—both as potential driver and potential barrier. This guide provides examples of MEDITECH EHR functionality that can be leveraged throughout the treatment process in support of your organization's biosimilar conversion goals.

| | MEDITECH EHR Functionality | Description |
|---|---|---|
| Patient Interface | Patient Portal | The Patient Portal is a patient communication vehicle that can be used to disseminate educational materials and treatment updates to patients. |
| | Patient Messaging | Empowers users to create direct customer communication through the Patient Messaging feature. This tool might be helpful in reducing the manual efforts of communicating a biosimilar adoption plan. |
| Provider Interface | Favorite Medications | Adding a product as a Favorite Medication allows a prescriber to reduce the number of clicks when selecting a commonly prescribed product. Prescribers may update their Favorite Medication selections to remove an originator and add a biosimilar product. |
| | Pursuit Lists | Creating a list of patients who meet certain clinical and demographic criteria provides an opportunity to proactively identify patients who might be eligible for a biosimilar formulation of the originator. Several reporting tools ranging from the Registries to BCA and Visual Insights are offered. More sophisticated reports can be created with the Data Repository Report Writer and Designer. |
| | Order Sets | Order Sets is the feature that governs the workflow associated with a particular therapeutic area. A biosimilar must be added to the relevant Order Set to be accessible for ordering by a physician. |
| | Clinical Decision Alerts (CDAs) | CDAs alert a provider during the ordering process that the organization prioritizes one treatment path for a given patient type. CDAs might be used to flag biosimilar-eligible patients for the prescriber at the time of ordering. |
| | Embedded Tools | Provides the ability to implement custom tools like cost calculators, screeners, and therapeutic equivalency agreements through Clinical Decision Support (CDS). |

**See next page for additional supporting EHR options.**

# Biosimilar implementation in MEDITECH EHR might include several components

**A hospital system might consider any of the options below to support its biosimilars initiative. These EHR and process changes might be implemented alone or in combination. With each of these options, a hospital system should consider whether the new workflow is appropriate for its structure and processes.**

## Benefits Verification Considerations

For all benefits verification options, consider who will be responsible for follow-through communications to providers and/or patients.

- **Verify commercial benefits in bulk:** Identify eligible* patients using **Pursuit Lists** based on payer type and medication. Verify benefits in the pharmacy or clinic setting in advance of ordering the biosimilar
- **Verify commercial benefits on a rolling basis:** Identify eligible* patients using **Pursuit Lists** based on payer type, medication, and imminent appointment date. Verify benefits in the pharmacy or clinic setting in advance of ordering the biosimilar

## Patient Communications Considerations

For all patient outreach options, consider who (providers, pharmacies, or others) the patient will be directed to with questions and ensure they are prepared.

- **Notify patients about biosimilar initiatives in advance of benefits verification:** Identify eligible* patients using **Pursuit Lists** and, through the **Patient Portal** or direct communication, notify patients that their provider might discuss the possibility of switching to a biosimilar at an upcoming visit
- **Notify patients after benefits have been verified:** After proactive benefits verification, leverage the **Patient Portal** and/or other means to notify patients that their provider will be discussing a biosimilar switch at an upcoming visit
- **Alert provider team at point of care:** Create a **CDA** that signals the need for a biosimilar switch discussion with a biosimilar-eligible patient at point of care

## Medication Ordering Considerations

- **Facilitate biosimilar ordering through Favorite Medications:** Encourage relevant providers to add the biosimilar as a **Favorite Medication** to reduce the number of clicks in the ordering process
- **Update Order Sets to reflect new workflow:** Add new workflow step to relevant **Order Sets** that allows providers to trigger a benefits verification for a biosimilar-eligible patient
- **Ensure availability in Order Sets:** Update **Order Sets** for the relevant disease states to include the biosimilar
- **Set preference for biosimilar in Order Sets:** Set biosimilar as the default order for biosimilar-eligible patients
- **Create provider notifications:** Create a **CDA** that identifies biosimilar-eligible patients for the provider at the time of the office visit
- **Create pharmacy notifications:** Create a **CDA** that alerts the pharmacy when the originator is ordered for a biosimilar-eligible patient
- **Add advanced order workflow:** Develop an embedded therapeutic equivalency protocol agreement that allows a pharmacist to initiate a biosimilar switch and captures the prescribing physician's approval

## Measuring the Impact of Your Biosimilars Initiative

- **Evaluate provider participation:** Use **Pursuit Lists** to identify providers that have or have not begun utilizing biosimilars

*Biosimilar eligibility will vary depending upon the organization's biosimilar conversion goals and other factors, including payer coverage, indication, and current patient therapy.

This piece was developed independently by Pfizer



PP-BIO-USA-0776

May 2021

Pfizer